October 24, 2018

Melinta Therapeutics taps director as interim CEO

PHOTO | VirMedica
PHOTO | VirMedica
John H. Johnson

New Haven's Melinta Therapeutics Inc., which develops antibiotics to treat serious bacterial infections, says it tapped one of its directors as interim CEO.

Melinta's board of directors this week appointed John H. Johnson effective immediately. Johnson succeeds Dan Wechsler, who is resigning as CEO, president and director to pursue other opportunities, the company said.

Melinta said its board and Wechsler mutually agreed to part ways.

Johnson takes over Melinta's lead post with over 30 years of biopharmaceutical industry, executive leadership and commercial experience at organizations including Johnson & Johnson, Eli Lilly & Co., ImClone and Pfizer, Inc.

He has previously served as director at Cempra Pharmaceuticals and Sucampo Pharmaceuticals Inc., and was president and CEO of biotech company Dendreon Corp., among other executive positions.

Johnson currently serves on the boards of Aveo Oncology, Histogenics Corporation, Portola Pharmaceuticals, Inc., and is chairman of Strongbridge Biopharma plc.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Should UConn Health merge with another hospital or hospital system?<>
Most Popular on Facebook
Copyright 2017 New England Business Media